GC Green Cross Wellbeing Completes Phase 3 Dosing of "Lainekju"

Multicenter Clinical Trial Concludes at 18 Domestic Institutions
Establishing Evidence for Intravenous Administration and High-Dose Dosing

GC Green Cross Wellbeing announced on April 23 that it has completed dosing for all participants in the Phase 3 clinical trial of Lainekju, a hydrolyzed human placenta extract formulation, in patients with chronic liver disease.

Advertising image for Lainexju product. GC Green Cross Wellbeing

This clinical trial was conducted as a multicenter study to evaluate dose escalation and the addition of new administration routes. A total of 18 domestic institutions, including Severance Hospital, participated. The main focus was on assessing the safety and efficacy of the high-dose intravenous injection method.

With dosing completed for all participants, the clinical trial has now begun analyzing the primary evaluation indicators. After obtaining the results, the company plans to apply for a change in approval with the Ministry of Food and Drug Safety.

Lainekju is currently administered via intramuscular and subcutaneous injections. If the intravenous administration method is added, it is expected that the choice of administration route can be tailored to the patient's condition.

A representative of GC Green Cross Wellbeing stated, "Completion of dosing in this Phase 3 clinical trial marks a strategic turning point to further enhance the market competitiveness of Lainekju," adding, "Based on the clinical data obtained through dose escalation, we will broaden treatment accessibility and continue to strengthen our market competitiveness."

This content was produced with the assistance of AI translation services.